Advertisement covers the 17th Conference on Retroviruses and Opportunistic Infections

Medical News

AIDS Vaccine Effects May Wear Off, Researchers Say

February 19, 2010

An AIDS vaccine candidate previously reported to have partial efficacy may have been most useful during a short timeframe, researchers announced Thursday at the 17th Conference on Retroviruses and Opportunistic Infections in San Francisco. The vaccine's temporary protection may have waned after a year or so, making it more difficult to assess its effects, reported Dr. Nelson Michael, of the Walter Reed Army Institute of Research, and colleagues.

"It is very likely that this vaccine only worked for a short period of time," Michael said. The trial in Thailand showed a 31 percent cut in infection risk over a longer timeframe of three years. "It is a weak, a modest effect but something that we can build on."

The vaccine is a combination of Sanofi-Pasteur's ALVAC canarypox/HIV vaccine and AIDSVAX, made by VaxGen and now owned by the nonprofit Global Solutions for Infectious Diseases.

Though the trial enrolled 16,000 volunteers, they were not individuals at particularly high risk of HIV infection, Michael said. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, and Michael will work together to design a trial in Asia or Africa to better determine whether the vaccine can be useful.

"Is [short-term protection] ideal? No," said Michael. "But it is true there are vaccines like the flu vaccine where you have to get them every year."

Researchers next will examine the blood of trial participants to look for clues as to why the vaccine worked. Labs around the world will be searching for correlates of efficacy, such as measurements of antibodies that indicate some immune system response, Michael said. Those results could take roughly a year.

Back to other news for February 2010

Adapted from:
02.18.2010; Maggie Fox

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
See Also
Investigational Vaccine Shows Modest Potential for Protecting Against HIV Infection
Basic Information on the RV144 Phase III HIV Vaccine Trial
HIV Vaccine Study First to Show Some Effectiveness in Preventing HIV (Press Release From U.S. Military HIV Research Program)

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.